JP2019527718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527718A5 JP2019527718A5 JP2019507303A JP2019507303A JP2019527718A5 JP 2019527718 A5 JP2019527718 A5 JP 2019527718A5 JP 2019507303 A JP2019507303 A JP 2019507303A JP 2019507303 A JP2019507303 A JP 2019507303A JP 2019527718 A5 JP2019527718 A5 JP 2019527718A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- independently
- heteroatoms
- sulfur
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 239000001301 oxygen Substances 0.000 claims 11
- 239000011593 sulfur Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 pyridadinyl Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371917P | 2016-08-08 | 2016-08-08 | |
| US62/371,917 | 2016-08-08 | ||
| PCT/US2017/045671 WO2018031434A1 (en) | 2016-08-08 | 2017-08-07 | Tlr7/8 antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527718A JP2019527718A (ja) | 2019-10-03 |
| JP2019527718A5 true JP2019527718A5 (enExample) | 2020-09-17 |
| JP7125385B2 JP7125385B2 (ja) | 2022-08-24 |
Family
ID=59656207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507303A Active JP7125385B2 (ja) | 2016-08-08 | 2017-08-07 | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10947214B2 (enExample) |
| EP (2) | EP3497094B1 (enExample) |
| JP (1) | JP7125385B2 (enExample) |
| KR (2) | KR20240019867A (enExample) |
| CN (1) | CN109563075B (enExample) |
| AU (1) | AU2017311047B2 (enExample) |
| CA (1) | CA3033240A1 (enExample) |
| DK (1) | DK3497094T3 (enExample) |
| ES (1) | ES2944573T3 (enExample) |
| IL (1) | IL264676B (enExample) |
| MX (1) | MX390698B (enExample) |
| RU (1) | RU2758686C2 (enExample) |
| SG (1) | SG11201900947RA (enExample) |
| WO (1) | WO2018031434A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| RU2758686C2 (ru) | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| WO2018089695A1 (en) * | 2016-11-11 | 2018-05-17 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| CA3086172A1 (en) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019233941A1 (en) * | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| JP7366994B2 (ja) * | 2018-07-23 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
| US11639352B2 (en) | 2018-09-04 | 2023-05-02 | Hoffman-La Roche Inc. | Benzothiazole compounds for the treatment of autoimmune diseases |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| WO2020048595A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| CN113271938A (zh) * | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| WO2021084022A1 (en) | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| CN114728976B (zh) * | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| WO2021099285A1 (en) * | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Triazatricycle compounds for the treatment of autoimmune disease |
| WO2021099406A1 (en) | 2019-11-20 | 2021-05-27 | F. Hoffmann-La Roche Ag | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| EP4069693B1 (en) | 2019-12-03 | 2024-03-20 | F. Hoffmann-La Roche AG | Hydropyrido[1,2-alpha]pyrazine compounds for the treatment of autoimmune diseases |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| EP4216949A4 (en) * | 2020-09-28 | 2024-12-11 | Yale University | Selective agonists of 5-ht2a receptor and methods of use |
| AU2022257039A1 (en) | 2021-04-16 | 2023-10-05 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| WO2023039464A1 (en) | 2021-09-10 | 2023-03-16 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN115073369A (zh) * | 2022-05-31 | 2022-09-20 | 汉瑞药业(荆门)有限公司 | 一种5-溴喹啉-8-甲醛的制备方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE812911C (de) * | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) * | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| JP2005511625A (ja) | 2001-11-14 | 2005-04-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 向精神薬としてのピラゾール誘導体 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| WO2004016576A1 (ja) | 2002-08-12 | 2004-02-26 | Takeda Pharmaceutical Company Limited | 縮合ベンゼン誘導体および用途 |
| CA2505873A1 (en) * | 2002-11-12 | 2004-05-27 | Pfizer Products Inc. | Quinoline derivatives |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| JPWO2005087749A1 (ja) * | 2004-03-15 | 2007-08-09 | 協和醗酵工業株式会社 | ２−アミノキナゾリン誘導体 |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| AU2005247405A1 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| US20080081817A1 (en) | 2004-07-23 | 2008-04-03 | Tanabe Seiyaku Co., Ltd. | Nitrogenous Fused Bicyclic Compound |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) * | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| WO2007097289A1 (ja) | 2006-02-20 | 2007-08-30 | Takeda Pharmaceutical Company Limited | 新規医薬 |
| EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| US20100004452A1 (en) | 2006-09-26 | 2010-01-07 | Barbara Bertani | 5-quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairment, psychotic disorders, anxiety, depression, etc. |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| PT2164825E (pt) * | 2007-06-05 | 2014-06-24 | Sanofi Sa | Derivados de di(hetero)arilciclo-hexano, sua preparação, sua utilização e composições farmacêuticas compreendendo os mesmos |
| CA2725416A1 (en) * | 2008-05-12 | 2009-11-19 | Amnestix, Inc. | Compounds for improving learning and memory |
| JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス， インコーポレイテッド | Ｃｄｋモジュレーター |
| US8735424B2 (en) | 2008-09-02 | 2014-05-27 | Novartis Ag | Bicyclic kinase inhibitors |
| WO2010063352A1 (en) | 2008-12-01 | 2010-06-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| EP2401275B1 (en) | 2009-02-24 | 2013-07-24 | Respiratorius AB | Naphthyridine derivatives having bronchodilating activity |
| WO2011009015A1 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| JP2013075834A (ja) * | 2011-09-29 | 2013-04-25 | Kowa Co | Ｔｌｒ９阻害活性を有するピラゾロピリミジン−７−アミン誘導体 |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| CA2916298C (en) | 2013-06-26 | 2021-10-12 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| RU2718876C2 (ru) * | 2013-08-23 | 2020-04-15 | Ньюфарма, Инк. | Некоторые химические соединения, композиции и способы |
| SG10201704327RA (en) * | 2013-10-14 | 2017-06-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| MX363708B (es) * | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| CA2933466A1 (en) | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US9938282B2 (en) | 2014-02-05 | 2018-04-10 | Stereokem, Inc. | Expedient synthesis of sitagliptin |
| NZ724691A (en) | 2014-03-24 | 2018-02-23 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| CN104945377A (zh) * | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| AR100137A1 (es) | 2014-04-22 | 2016-09-14 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| US10590086B2 (en) | 2014-11-03 | 2020-03-17 | Iomet Pharma Ltd. | Pharmaceutical compound |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| BR112017009648A2 (pt) * | 2014-11-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto. |
| WO2016087593A1 (en) * | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| US10167270B2 (en) | 2015-07-01 | 2019-01-01 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| WO2017147328A1 (en) * | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| RU2758686C2 (ru) | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| WO2018118781A1 (en) * | 2016-12-20 | 2018-06-28 | Fmc Corporation | Fungicidal oxadiazoles |
| US11050028B2 (en) * | 2017-01-24 | 2021-06-29 | Universal Display Corporation | Organic electroluminescent materials and devices |
| CN110944990B (zh) | 2017-07-18 | 2024-06-18 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| CA3086172A1 (en) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| MX2021000093A (es) | 2018-07-31 | 2021-03-25 | Merck Patent Gmbh | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. |
-
2017
- 2017-08-07 RU RU2019105719A patent/RU2758686C2/ru active
- 2017-08-07 US US15/670,068 patent/US10947214B2/en active Active
- 2017-08-07 CA CA3033240A patent/CA3033240A1/en active Pending
- 2017-08-07 EP EP17754553.0A patent/EP3497094B1/en active Active
- 2017-08-07 SG SG11201900947RA patent/SG11201900947RA/en unknown
- 2017-08-07 JP JP2019507303A patent/JP7125385B2/ja active Active
- 2017-08-07 CN CN201780049341.XA patent/CN109563075B/zh active Active
- 2017-08-07 MX MX2019001096A patent/MX390698B/es unknown
- 2017-08-07 KR KR1020247004013A patent/KR20240019867A/ko active Pending
- 2017-08-07 DK DK17754553.0T patent/DK3497094T3/da active
- 2017-08-07 ES ES17754553T patent/ES2944573T3/es active Active
- 2017-08-07 AU AU2017311047A patent/AU2017311047B2/en active Active
- 2017-08-07 WO PCT/US2017/045671 patent/WO2018031434A1/en not_active Ceased
- 2017-08-07 EP EP23154971.8A patent/EP4198031A1/en active Pending
- 2017-08-07 KR KR1020197006660A patent/KR102635885B1/ko active Active
-
2019
- 2019-02-05 IL IL264676A patent/IL264676B/en unknown
-
2020
- 2020-09-18 US US16/948,432 patent/US11512069B2/en active Active
- 2020-09-21 US US16/948,467 patent/US20210002256A1/en active Pending
-
2024
- 2024-07-24 US US18/782,269 patent/US20240383876A1/en active Pending